Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

The molecular origin and taxonomy of mucinous ovarian carcinoma.

Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Anglesio MS, Au-Yeung G, Böhm M, Bowtell DDL, Brand A, Chenevix-Trench G, Christie M, Chiew YE, Churchman M, DeFazio A, Demeo R, Dudley R, Fairweather N, Fedele CG, Fereday S, Fox SB, Gilks CB, Gourley C, Hacker NF, Hadley AM, Hendley J, Ho GY, Hughes S, Hunstman DG, Hunter SM, Jobling TW, Kalli KR, Kaufmann SH, Kennedy CJ, Köbel M, Le Page C, Li J, Lupat R, McNally OM, McAlpine JN, Mes-Masson AM, Mileshkin L, Provencher DM, Pyman J, Rahimi K, Rowley SM, Salazar C, Samimi G, Saunders H, Semple T, Sharma R, Sharpe AJ, Stephens AN, Thio N, Torres MC, Traficante N, Xing Z, Zethoven M, Antill YC, Scott CL, Campbell IG, Gorringe KL.

Nat Commun. 2019 Sep 2;10(1):3935. doi: 10.1038/s41467-019-11862-x.

2.

A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.

Meagher NS, Wang L, Rambau PF, Intermaggio MP, Huntsman DG, Wilkens LR, El-Bahrawy MA, Ness RB, Odunsi K, Steed H, Herpel E, Anglesio MS, Zhang B, Lambie N, Swerdlow AJ, Lubiński J, Vierkant RA, Goode EL, Menon U, Toloczko-Grabarek A, Oszurek O, Bilic S, Talhouk A, García-Closas M, Wang Q, Tan A, Farrell R, Kennedy CJ, Jimenez-Linan M, Sundfeldt K, Etter JL, Menkiszak J, Goodman MT, Klonowski P, Leung Y, Winham SJ, Moysich KB, Behrens S, Kluz T, Edwards RP, Gronwald J, Modugno F, Hernandez BY, Chow C, Kelemen LE, Keeney GL, Carney ME, Natanzon Y, Robertson G, Sharma R, Gayther SA, Alsop J, Luk H, Karpinskyj C, Campbell I, Sinn P, Gentry-Maharaj A, Coulson P, Chang-Claude J, Shah M, Widschwendter M, Tang K, Schoemaker MJ, Koziak JM, Cook LS, Brenton JD, Daley F, Kristjansdottir B, Mateoiu C, Larson MC, Harnett PR, Jung A, deFazio A, Gorringe KL, Pharoah PDP, Minoo P, Stewart C, Bathe OF, Gui X, Cohen P, Ramus SJ, Köbel M.

Mod Pathol. 2019 Jun 25. doi: 10.1038/s41379-019-0302-0. [Epub ahead of print]

PMID:
31239549
3.

Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ.

Toss MS, Miligy IM, Gorringe KL, Aleskandarany MA, Alkawaz A, Mittal K, Aneja R, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2019 Oct;32(10):1460-1472. doi: 10.1038/s41379-019-0286-9. Epub 2019 Jun 7.

PMID:
31175327
4.

Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study.

Toss MS, Miligy IM, Gorringe KL, AlKawaz A, Mittal K, Aneja R, Ellis IO, Green AR, Roxanis I, Rakha EA.

Mod Pathol. 2019 Oct;32(10):1473-1485. doi: 10.1038/s41379-019-0296-7. Epub 2019 Jun 7.

PMID:
31175326
5.

The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution.

Miligy IM, Toss MS, Gorringe KL, Lee AHS, Ellis IO, Green AR, Rakha EA.

Br J Cancer. 2019 May;120(11):1075-1082. doi: 10.1038/s41416-019-0436-3. Epub 2019 May 8.

PMID:
31065110
6.

Combined tumor sequencing and case/control analyses of RAD51C in breast cancer.

Li N, McInerny S, Zethoven M, Cheasley D, Lim BWX, Rowley SM, Devereux L, Grewal N, Ahmadloo S, Byrne D, Lee JEA, Li J, Fox SB, John T, Antill Y, Gorringe KL, James PA, Campbell IG.

J Natl Cancer Inst. 2019 Apr 5. pii: djz045. doi: 10.1093/jnci/djz045. [Epub ahead of print]

PMID:
30949688
7.

Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma.

Kader T, Hill P, Zethoven M, Goode DL, Elder K, Thio N, Doyle M, Semple T, Sufyan W, Byrne DJ, Pang JB, Murugasu A, Miligy IM, Green AR, Rakha EA, Fox SB, Mann GB, Campbell IG, Gorringe KL.

J Pathol. 2019 Jul;248(3):326-338. doi: 10.1002/path.5262. Epub 2019 Apr 22.

PMID:
30843206
8.

Molecular comparison of interval and screen-detected breast cancers.

Cheasley D, Li N, Rowley SM, Elder K, Mann GB, Loi S, Savas P, Goode DL, Kader T, Zethoven M, Semple T, Fox SB, Pang JM, Byrne D, Devereux L, Nickson C, Procopio P, Lee G, Hughes S, Saunders H, Fujihara KM, Kuykhoven K, Connaughton J, James PA, Gorringe KL, Campbell IG.

J Pathol. 2019 Jun;248(2):243-252. doi: 10.1002/path.5251. Epub 2019 Mar 8.

PMID:
30746706
9.

The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ.

Toss MS, Miligy IM, Haj-Ahmad R, Gorringe KL, AlKawaz A, Mittal K, Ellis IO, Green AR, Rakha EA.

Histopathology. 2019 Jun;74(7):1025-1035. doi: 10.1111/his.13835. Epub 2019 Apr 14.

PMID:
30725481
10.

When Is "Type I" Ovarian Cancer Not "Type I"? Indications of an Out-Dated Dichotomy.

Salazar C, Campbell IG, Gorringe KL.

Front Oncol. 2018 Dec 21;8:654. doi: 10.3389/fonc.2018.00654. eCollection 2018. Review.

11.

Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ.

Toss MS, Miligy IM, Gorringe KL, McCaffrey L, AlKawaz A, Abidi A, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2019 May;32(5):639-649. doi: 10.1038/s41379-018-0180-x. Epub 2018 Nov 14.

PMID:
30429518
12.

Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).

Toss MS, Miligy IM, Gorringe KL, AlKawaz A, Khout H, Ellis IO, Green AR, Rakha EA.

Br J Cancer. 2018 Dec;119(12):1518-1526. doi: 10.1038/s41416-018-0337-x. Epub 2018 Nov 9.

PMID:
30410060
13.

Mutations in RECQL are not associated with breast cancer risk in an Australian population.

Li N, Rowley SM, Goode DL, Amarasinghe KC, McInerny S, Devereux L; LifePool Investigators, Wong-Brown MW, Lupat R, Lee JEA, Hughes S, Thompson ER, Zethoven M, Li J, Trainer AH, Gorringe KL, Scott RJ, James PA, Campbell IG.

Nat Genet. 2018 Oct;50(10):1346-1348. doi: 10.1038/s41588-018-0206-9. No abstract available.

PMID:
30224651
14.

Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ.

Miligy IM, Gorringe KL, Toss MS, Al-Kawaz AA, Simpson P, Diez-Rodriguez M, Nolan CC, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2018 Dec;31(12):1807-1815. doi: 10.1038/s41379-018-0086-7. Epub 2018 Jun 28.

PMID:
29955142
15.

Functional and genomic characterisation of a xenograft model system for the study of metastasis in triple-negative breast cancer.

Johnstone CN, Pattison AD, Gorringe KL, Harrison PF, Powell DR, Lock P, Baloyan D, Ernst M, Stewart AG, Beilharz TH, Anderson RL.

Dis Model Mech. 2018 May 29;11(5). pii: dmm032250. doi: 10.1242/dmm.032250.

16.

Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape.

Kader T, Hill P, Rakha EA, Campbell IG, Gorringe KL.

Breast Cancer Res. 2018 May 2;20(1):39. doi: 10.1186/s13058-018-0967-1. Review.

17.

Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis.

Kurozumi S, Joseph C, Sonbul S, Gorringe KL, Pigera M, Aleskandarany MA, Diez-Rodriguez M, Nolan CC, Fujii T, Shirabe K, Kuwano H, Storr S, Martin SG, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2018 Aug;170(3):525-533. doi: 10.1007/s10549-018-4777-z. Epub 2018 Apr 9.

PMID:
29633055
18.

Molecular analysis of PALB2-associated breast cancers.

Lee JEA, Li N, Rowley SM, Cheasley D, Zethoven M, McInerny S, Gorringe KL, James PA, Campbell IG.

J Pathol. 2018 May;245(1):53-60. doi: 10.1002/path.5055. Epub 2018 Mar 30.

PMID:
29431189
19.

Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs.

Li N, Rowley SM, Thompson ER, McInerny S, Devereux L, Amarasinghe KC, Zethoven M, Lupat R, Goode D, Li J, Trainer AH, Gorringe KL, James PA, Campbell IG.

Breast Cancer Res. 2018 Jan 9;20(1):3. doi: 10.1186/s13058-017-0929-z.

20.

Invasion in breast lesions: the role of the epithelial-stroma barrier.

Rakha EA, Miligy IM, Gorringe KL, Toss MS, Green AR, Fox SB, Schmitt FC, Tan PH, Tse GM, Badve S, Decker T, Vincent-Salomon A, Dabbs DJ, Foschini MP, Moreno F, Wentao Y, Geyer FC, Reis-Filho JS, Pinder SE, Lakhani SR, Ellis IO.

Histopathology. 2018 Jun;72(7):1075-1083. doi: 10.1111/his.13446. Epub 2018 Feb 13. Review.

PMID:
29197112
21.

LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness.

Pang JB, Molania R, Chand A, Knower K, Takano EA, Byrne DJ, Mikeska T, Millar EKA, Lee CS, O'Toole SA, Clyne C, Gorringe KL, Dobrovic A, Fox SB.

Oncotarget. 2017 Jul 28;8(48):83626-83636. doi: 10.18632/oncotarget.18886. eCollection 2017 Oct 13.

22.

Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis.

Gorringe KL, Fox SB.

Front Oncol. 2017 Oct 23;7:248. doi: 10.3389/fonc.2017.00248. eCollection 2017. Review.

23.

BRCA2 carriers with male breast cancer show elevated tumour methylation.

Deb S, Gorringe KL, Pang JB, Byrne DJ, Takano EA, Investigators K, Dobrovic A, Fox SB.

BMC Cancer. 2017 Sep 11;17(1):641. doi: 10.1186/s12885-017-3632-7.

24.

Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features.

Hendry S, Pang JB, Byrne DJ, Lakhani SR, Cummings MC, Campbell IG, Mann GB, Gorringe KL, Fox SB.

Clin Cancer Res. 2017 Sep 1;23(17):5210-5217. doi: 10.1158/1078-0432.CCR-17-0743. Epub 2017 Jun 13.

25.

Phenotypic characterisation of breast cancer: the role of CDC42.

Chrysanthou E, Gorringe KL, Joseph C, Craze M, Nolan CC, Diez-Rodriguez M, Green AR, Rakha EA, Ellis IO, Mukherjee A.

Breast Cancer Res Treat. 2017 Jul;164(2):317-325. doi: 10.1007/s10549-017-4267-8. Epub 2017 Apr 27.

26.

Chemokine (C-C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma.

Sonbul SN, Gorringe KL, Aleskandarany MA, Mukherjee A, Green AR, Ellis IO, Rakha EA.

J Pathol Clin Res. 2017 Mar 30;3(2):105-114. doi: 10.1002/cjp2.65. eCollection 2017 Apr.

27.

Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.

Pang JB, Savas P, Fellowes AP, Mir Arnau G, Kader T, Vedururu R, Hewitt C, Takano EA, Byrne DJ, Choong DY, Millar EK, Lee CS, O'Toole SA, Lakhani SR, Cummings MC, Mann GB, Campbell IG, Dobrovic A, Loi S, Gorringe KL, Fox SB.

Mod Pathol. 2017 Jul;30(7):952-963. doi: 10.1038/modpathol.2017.21. Epub 2017 Mar 24.

28.

Erratum to: Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors.

Ryland GL, Hunter SM, Doyle MA, Caramia F, Li J, Rowley SM, Christie M, Allan PE, Stephens AN, Bowtell DD; Australian Ovarian Cancer Study Group, Campbell IG, Gorringe KL.

Genome Med. 2017 Jan 12;9(1):1. doi: 10.1186/s13073-016-0392-y. No abstract available.

29.

Copy number analysis by low coverage whole genome sequencing using ultra low-input DNA from formalin-fixed paraffin embedded tumor tissue.

Kader T, Goode DL, Wong SQ, Connaughton J, Rowley SM, Devereux L, Byrne D, Fox SB, Mir Arnau G, Tothill RW, Campbell IG, Gorringe KL.

Genome Med. 2016 Nov 15;8(1):121.

30.

Reevaluation of RINT1 as a breast cancer predisposition gene.

Li N, Thompson ER, Rowley SM, McInerny S, Devereux L, Goode D, Investigators L, Wong-Brown MW, Scott RJ, Trainer AH, Gorringe KL, James PA, Campbell IG.

Breast Cancer Res Treat. 2016 Sep;159(2):385-92. doi: 10.1007/s10549-016-3944-3. Epub 2016 Aug 20.

PMID:
27544226
31.

Reply to the Baader-Meinhof phenomenon in ductal carcinoma in situ of the breast.

Pang JM, Gorringe KL, Fox SB.

Histopathology. 2016 Sep;69(3):523-4. doi: 10.1111/his.12968. Epub 2016 May 5. No abstract available.

PMID:
26990228
32.

Ductal carcinoma in situ - update on risk assessment and management.

Pang JM, Gorringe KL, Fox SB.

Histopathology. 2016 Jan;68(1):96-109. doi: 10.1111/his.12796. Review.

PMID:
26768032
33.

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.

Hunter SM, Anglesio MS, Ryland GL, Sharma R, Chiew YE, Rowley SM, Doyle MA, Li J, Gilks CB, Moss P, Allan PE, Stephens AN, Huntsman DG, deFazio A, Bowtell DD; Australian Ovarian Cancer Study Group, Gorringe KL, Campbell IG.

Oncotarget. 2015 Nov 10;6(35):37663-77. doi: 10.18632/oncotarget.5438.

34.

Reevaluation of the BRCA2 truncating allele c.9976A > T (p.Lys3326Ter) in a familial breast cancer context.

Thompson ER, Gorringe KL, Rowley SM, Li N, McInerny S, Wong-Brown MW, Devereux L, Li J; Lifepool Investigators, Trainer AH, Mitchell G, Scott RJ, James PA, Campbell IG.

Sci Rep. 2015 Oct 12;5:14800. doi: 10.1038/srep14800.

35.

Copy number analysis of ductal carcinoma in situ with and without recurrence.

Gorringe KL, Hunter SM, Pang JM, Opeskin K, Hill P, Rowley SM, Choong DY, Thompson ER, Dobrovic A, Fox SB, Mann GB, Campbell IG.

Mod Pathol. 2015 Sep;28(9):1174-84. doi: 10.1038/modpathol.2015.75. Epub 2015 Jun 19.

36.

Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls.

Thompson ER, Gorringe KL, Rowley SM, Wong-Brown MW, McInerny S, Li N, Trainer AH, Devereux L, Doyle MA, Li J, Lupat R, Delatycki MB; LifePool Investigators, Mitchell G, James PA, Scott RJ, Campbell IG.

Breast Cancer Res. 2015 Aug 19;17:111. doi: 10.1186/s13058-015-0627-7.

37.

Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors.

Ryland GL, Hunter SM, Doyle MA, Caramia F, Li J, Rowley SM, Christie M, Allan PE, Stephens AN, Bowtell DD; Australian Ovarian Cancer Study Group, Campbell IG, Gorringe KL.

Genome Med. 2015 Aug 7;7(1):87. doi: 10.1186/s13073-015-0210-y. eCollection 2015. Erratum in: Genome Med. 2017 Jan 12;9(1):1.

38.

Loss of heterozygosity: what is it good for?

Ryland GL, Doyle MA, Goode D, Boyle SE, Choong DY, Rowley SM, Li J; Australian Ovarian Cancer Study Group, Bowtell DD, Tothill RW, Campbell IG, Gorringe KL.

BMC Med Genomics. 2015 Aug 1;8:45. doi: 10.1186/s12920-015-0123-z.

39.

Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast.

Pang JM, Gorringe KL, Wong SQ, Dobrovic A, Campbell IG, Fox SB.

Breast Cancer Res. 2015 Jun 16;17:80. doi: 10.1186/s13058-015-0586-z. Review.

40.

Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.

Davis SJ, Sheppard KE, Anglesio MS, George J, Traficante N, Fereday S, Intermaggio MP, Menon U, Gentry-Maharaj A, Lubinski J, Gronwald J, Pearce CL, Pike MC, Wu A, Kommoss S, Pfisterer J, du Bois A, Hilpert F, Ramus SJ, Bowtell DD, Huntsman DG, Pearson RB, Simpson KJ, Campbell IG, Gorringe KL.

Mol Cancer Ther. 2015 Jun;14(6):1495-503. doi: 10.1158/1535-7163.MCT-15-0039. Epub 2015 Apr 7. Erratum in: Mol Cancer Ther. 2017 Mar;16(3):551.

41.

Genomic aberrations of BRCA1-mutated fallopian tube carcinomas.

Hunter SM, Ryland GL, Moss P; kConFab Investigators, Gorringe KL, Campbell IG.

Am J Pathol. 2014 Jun;184(6):1871-6. doi: 10.1016/j.ajpath.2014.02.013. Epub 2014 Apr 13.

PMID:
24726640
42.

Identifying associations between genomic alterations in tumors.

George J, Gorringe KL, Smyth GK, Bowtell DD.

Methods Mol Biol. 2013;1049:9-19. doi: 10.1007/978-1-62703-547-7_2.

PMID:
23913205
43.

Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer.

Davis SJ, Sheppard KE, Pearson RB, Campbell IG, Gorringe KL, Simpson KJ.

Clin Cancer Res. 2013 Mar 15;19(6):1411-21. doi: 10.1158/1078-0432.CCR-12-3433. Epub 2013 Jan 29.

44.

RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary.

Ryland GL, Hunter SM, Doyle MA, Rowley SM, Christie M, Allan PE, Bowtell DD; Australian Ovarian Cancer Study Group, Gorringe KL, Campbell IG.

J Pathol. 2013 Feb;229(3):469-76. doi: 10.1002/path.4134.

PMID:
23096461
45.

Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations.

Hunter SM, Gorringe KL, Christie M, Rowley SM, Bowtell DD; Australian Ovarian Cancer Study Group, Campbell IG.

Clin Cancer Res. 2012 Oct 1;18(19):5267-77. doi: 10.1158/1078-0432.CCR-12-1103. Epub 2012 Aug 13.

46.

Analysis of KLLN as a high-penetrance breast cancer predisposition gene.

Thompson ER, Gorringe KL, Choong DY, Eccles DM; kConFab, Mitchell G, Campbell IG.

Breast Cancer Res Treat. 2012 Jul;134(2):543-7. doi: 10.1007/s10549-012-2088-3. Epub 2012 May 13.

PMID:
22580995
47.

MicroRNA genes and their target 3'-untranslated regions are infrequently somatically mutated in ovarian cancers.

Ryland GL, Bearfoot JL, Doyle MA, Boyle SE, Choong DY, Rowley SM; Australian Ovarian Cancer Study Group, Tothill RW, Gorringe KL, Campbell IG.

PLoS One. 2012;7(4):e35805. doi: 10.1371/journal.pone.0035805. Epub 2012 Apr 20.

48.

CONTRA: copy number analysis for targeted resequencing.

Li J, Lupat R, Amarasinghe KC, Thompson ER, Doyle MA, Ryland GL, Tothill RW, Halgamuge SK, Campbell IG, Gorringe KL.

Bioinformatics. 2012 May 15;28(10):1307-13. doi: 10.1093/bioinformatics/bts146. Epub 2012 Apr 2.

49.

An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.

Kinross KM, Montgomery KG, Kleinschmidt M, Waring P, Ivetac I, Tikoo A, Saad M, Hare L, Roh V, Mantamadiotis T, Sheppard KE, Ryland GL, Campbell IG, Gorringe KL, Christensen JG, Cullinane C, Hicks RJ, Pearson RB, Johnstone RW, McArthur GA, Phillips WA.

J Clin Invest. 2012 Feb;122(2):553-7. doi: 10.1172/JCI59309. Epub 2012 Jan 3.

50.

Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma.

Johnson CE, Gorringe KL, Thompson ER, Opeskin K, Boyle SE, Wang Y, Hill P, Mann GB, Campbell IG.

Breast Cancer Res Treat. 2012 Jun;133(3):889-98. doi: 10.1007/s10549-011-1835-1. Epub 2011 Nov 4.

PMID:
22052326

Supplemental Content

Loading ...
Support Center